Demographics and β-globin genotype of study patients
| Matched short- and standard-interval patients . | |||||
|---|---|---|---|---|---|
| Patient . | Sex . | Age (y) . | Sickle cell genotype . | Average infusion center visits per month (standard-interval vs short-interval) . | Average MME of home opioid regimen . |
| 1 | Female | 23 | HbS/β+ thalassemia | 0.56 (standard); 0.13 (short) | 60 |
| 2 | Male | 28 | HbSS | 0.44 (standard); 0.38 (short) | 180 |
| 3 | Male | 31 | HbSS | 0.56 (standard); 0.25 (short) | 150 |
| 4 | Female | 27 | HbSS | 0.56 (standard); 0.63 (short) | 125 |
| 5 | Male | 24 | HbS/β+ thalassemia | 0.67 (standard); 0.13 (short) | 64 |
| 6 | Female | 31 | HbSS | 0.22 (standard); 0.13 (short) | 64 |
| 7 | Female | 40 | HbSS | 0.33 (standard); 0.25 (short) | 48 |
| Average infusion center visits per month | Average MME in matched patients | ||||
| 0.48 (standard); 0.27 (short) | 99 | ||||
| Matched short- and standard-interval patients . | |||||
|---|---|---|---|---|---|
| Patient . | Sex . | Age (y) . | Sickle cell genotype . | Average infusion center visits per month (standard-interval vs short-interval) . | Average MME of home opioid regimen . |
| 1 | Female | 23 | HbS/β+ thalassemia | 0.56 (standard); 0.13 (short) | 60 |
| 2 | Male | 28 | HbSS | 0.44 (standard); 0.38 (short) | 180 |
| 3 | Male | 31 | HbSS | 0.56 (standard); 0.25 (short) | 150 |
| 4 | Female | 27 | HbSS | 0.56 (standard); 0.63 (short) | 125 |
| 5 | Male | 24 | HbS/β+ thalassemia | 0.67 (standard); 0.13 (short) | 64 |
| 6 | Female | 31 | HbSS | 0.22 (standard); 0.13 (short) | 64 |
| 7 | Female | 40 | HbSS | 0.33 (standard); 0.25 (short) | 48 |
| Average infusion center visits per month | Average MME in matched patients | ||||
| 0.48 (standard); 0.27 (short) | 99 | ||||
| Short-interval-only patients . | |||||
|---|---|---|---|---|---|
| Patient . | Sex . | Age (y) . | Sickle cell genotype . | Average infusion center visits per month (short-interval only) . | Average MME of home opioid regimen . |
| 8 | Male | 23 | HbSS | 0.13 (short) | 45 |
| 9 | Male | 36 | HbSS | 0.13 (short) | 105 |
| 10 | Female | 34 | HbSC | 0.25 (short) | 140 |
| 11 | Female | 26 | HbSS | 0.5 (short) | 40 |
| 12 | Female | 37 | HbSC | 0.25 (short) | 0 |
| 13 | Female | 57 | HbSS | 0.13 (short) | 15 |
| 14 | Female | 40 | HbSS | 0.5 (short) | 48 |
| 15 | Male | 41 | HbSC | 0.63 (short) | 68 |
| 16 | female | 36 | HbSC | 0.13 (short) | 45 |
| Average infusion center visits per month(short-interval only) | Average MME in short-interval only patients | ||||
| 0.29 (short) | 56 | ||||
| Total patients: 16 | 62.5% female; 37.5% male | Mean, 33.4; range, 23-57 | HbSS 62.5% HbSC 25% HbS/β+ thalassemia 12.5% | — | — |
| Short-interval-only patients . | |||||
|---|---|---|---|---|---|
| Patient . | Sex . | Age (y) . | Sickle cell genotype . | Average infusion center visits per month (short-interval only) . | Average MME of home opioid regimen . |
| 8 | Male | 23 | HbSS | 0.13 (short) | 45 |
| 9 | Male | 36 | HbSS | 0.13 (short) | 105 |
| 10 | Female | 34 | HbSC | 0.25 (short) | 140 |
| 11 | Female | 26 | HbSS | 0.5 (short) | 40 |
| 12 | Female | 37 | HbSC | 0.25 (short) | 0 |
| 13 | Female | 57 | HbSS | 0.13 (short) | 15 |
| 14 | Female | 40 | HbSS | 0.5 (short) | 48 |
| 15 | Male | 41 | HbSC | 0.63 (short) | 68 |
| 16 | female | 36 | HbSC | 0.13 (short) | 45 |
| Average infusion center visits per month(short-interval only) | Average MME in short-interval only patients | ||||
| 0.29 (short) | 56 | ||||
| Total patients: 16 | 62.5% female; 37.5% male | Mean, 33.4; range, 23-57 | HbSS 62.5% HbSC 25% HbS/β+ thalassemia 12.5% | — | — |
Of the 16 patients, 7 had matched short- and standard-interval data, whereas the remaining 9 were treated with only short-interval pain plans. All patients received their primary hematologic care at the Penn Comprehensive Sickle Cell Program (CSCP) and received treatment for VOEs at the Hematology-Oncology Evaluation Center (OEC) at the Hospital of the University of Pennsylvania. The average number of infusion center visits per month were calculated for each patient in the standard-interval time frame (1 March 2020 to 31 December 2020; 10 mo) vs the short-interval time frame (1 January 2021 to 31 August 2021; 8 mo).